I am attending AUTM’s annual conference in Las Vegas, so Mike Moberly’s February 18 blog is apropos. The models for IP development are changing, and license agreements are getting ever more complex. What factors will affect IP value from early to later stage development? As attendees here agree, it’s all about risk… identifying and mitigating risks, and finding partners who are willing to assume different degrees of risk. (Many think you cannot depend on large Biotech companies anymore, at least not like you used to be able to.)
Some vendors attending offer IP audit services, to make sure the complexities of today’s deals are yielding what was promised. Moberly feels things have changed so much, IP audits, as presently constituted, simply aren’t enough. Here, read it in his words.